- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04795310
Clinical Observation of Pulsed Dye Laser and Intense Pulsed Light in Treating Facial Telangiectasia
A Clinical Observation on the Efficacy and Safety of Pulsed Dye Laser and Intense Pulsed Light With Different Wavelength Bands in the Treatment of Facial Telangiectasia: a Retrospective, Self-controlled Trial
- Facial telangiectasia is one of the common skin vascular lesions characterized by dilated cutaneous vasculatures in the skin surface or mucous membranes. Lesions are generally sensitive to exposure of cold, heat and sun. Those distinct small dilated blood vessels are cosmetically disfiguring for patients which require an effective solution. The traditional management options for facial telangiectasia include cryotherapy, CO2 laser, topical agent, oral estrogens, electrosurgery, and radioactive treatment. However, inadequate outcomes and severe adversaries are the major concerns to patients and physicians.
Pulsed dye laser (PDL) is effective for vasodilatory diseases, especially for the superficial to middle layers of the dermis.
The intense pulsed light source is an alternative or supplement to the already existing laser devices that are part of the laser surgeon's repertoire. The broad wavelength spectrum and variable pulse duration allow greater penetration depths to be reached without damaging surrounding tissue and thus enhance the versatility of this system.
- This study aims to compare the clearance efficacy of facial telangiectasia using PDL (595nm) with IPL configured by various wavelength bands, including M22 vascular filter (530-650nm and 900-1200nm), M22 560 (560-1200nm), M22 590 (590-1200nm) .
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Shaanxi
-
Xi'an, Shaanxi, China, 710032
- Xijing Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects must be clinically diagnosed with facial telangiectasia
- No other external treatment was performed before the injury was treated
Exclusion Criteria:
- subjects with a recent history of exposure to sunlight
- subjects allergic to topical anesthesia
- subjects with scar constitution
- subjects with skin malignant tumors or precancerous lesions
- subjects with diabetes, heart disease, epilepsy, connective tissue disease, etc
- subjects who Pregnant or breast feeding
- subjects with recent skin infections (such as viruses, bacteria, etc.)
- other methods are being used to treat subjects with similar diseases
- subject who have taken isotretinoin A in the past year
- subject with facial dermatitis
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Pulsed Dye Laser
PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD)
|
PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD). IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.
Other Names:
|
Active Comparator: Intense Pulsed Light
Vascular wavelength bands of 530-650nm and 900-1200nm
|
PDL (Vbeam perfecta, 595 nm, Candela Corporation, Wayland, MA) was used with energy dosages of 9-11J/cm2, pulse durations of 10ms/20ms, and 7 or 10 mm handpieces with dynamic cooling device (DCD). IPL device (M22, Lumenis Limited, Yokneam, Israel) with integration of sapphire ChillTip system for epidermal cooling were used in the study. Three wavelength bands were configured: 560-1200 nm, 590-1200 nm, and vascular wavelength bands of 530-650nm and 900-1200nm. All the treatment handpieces had a spot size of 15mm×35mm, fluence of 9-17J/cm², pulse duration of 4.0-6.0ms and pulse delay of 20-40ms, underwent the M22 advanced optimal pulse technology (AOPT) treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Severity index of facial telangiectasia
Time Frame: 6months
|
|
6months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gang Wang, Prof, Dermatology Derpartment of Xijing Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XijingH-PF-20192074-C-1
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Telangiectasia
-
The Lowy Medical Research Institute LimitedActive, not recruiting
-
Neurotech PharmaceuticalsCompletedMacular TelangiectasiaUnited States, Australia
-
Neurotech PharmaceuticalsThe Lowy Medical Research Institute LimitedCompletedIdiopathic Juxtafoveal TelangiectasiaUnited States
-
Centre Hospitalier Universitaire DijonRecruitingMacular TelangiectasiaFrance
-
Paul S. BernsteinCompletedIdiopathic Juxtafoveal TelangiectasiaUnited States
-
Manhattan Eye, Ear & Throat HospitalAlcon ResearchCompletedIdiopathic Perifoveal TelangiectasiaUnited States
-
The Lowy Medical Research Institute LimitedActive, not recruitingMacular Telangiectasia Type 2United States, United Kingdom
-
Neurotech PharmaceuticalsCompletedMacular Telangiectasia Type 2United States, Australia, Germany
-
Neurotech PharmaceuticalsCompletedA Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol AMacular Telangiectasia Type 2United States, United Kingdom, Australia, France
-
National Eye Institute (NEI)CompletedMacular TelangiectasiaUnited States
Clinical Trials on Pulsed dye laser
-
Taipei Medical University WanFang HospitalTerminated
-
Northwestern UniversityEnrolling by invitation
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Candela CorporationCompleted
-
University of California, IrvineBeckman Laser Institute University of California IrvineCompletedPort Wine StainsUnited States
-
University Hospital, CaenCompleted
-
University of ManitobaRecruiting
-
Mahidol UniversityDermatological Society of ThailandCompletedHypertrophic Scars | KeloidsThailand
-
Bispebjerg HospitalUnknownPulsed Dye Laser and Intense Pulsed Light (IPL) for the Treatment of Telangiectasia and Skin RednessErythema | TelangiectasisDenmark
-
Bispebjerg HospitalTerminated
-
Tehran University of Medical SciencesWithdrawnScarIran, Islamic Republic of